NCT07223944 RECRUITING A Gaucher Disease Gene Therapy Trial With FLT201
Spur Therapeutics n=45
NCT07847411 NOT YET RECRUITING Study of Velaglucerase Beta ERT in Children With Gaucher Disease
CANbridge Life Sciences Ltd. n=10
NCT07885917 NOT YET RECRUITING Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
Azafaros B.V. n=218
NCT05529992 COMPLETED A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease
Takeda n=20
NCT06211478 COMPLETED Role of Vitamin E in Gaucher Disease Patients
Ain Shams University n=40
NCT05815004 WITHDRAWN An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3
AVROBIO
NCT01422187 COMPLETED A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease
Pfizer n=19
NCT02536755 COMPLETED Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies
Genzyme, a Sanofi Company n=31
NCT01614574 COMPLETED Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease
Shire n=6
NCT01842841 COMPLETED Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease
Shire n=5
NCT00635427 COMPLETED An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
Shire n=95
NCT00553631 COMPLETED Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
Shire n=34
NCT00712348 COMPLETED Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
Pfizer n=31
NCT00705939 COMPLETED Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial
Pfizer n=45
NCT01411228 COMPLETED A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
Pfizer n=15
NCT02770625 COMPLETED Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease
ISU Abxis Co., Ltd. n=8
NCT00891202 COMPLETED A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)
Genzyme, a Sanofi Company n=40
NCT01074944 COMPLETED A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)
Genzyme, a Sanofi Company n=170
NCT00943111 COMPLETED A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)
Genzyme, a Sanofi Company n=160
NCT01161914 WITHDRAWN The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease
ISU Abxis Co., Ltd.
